

INDEPENDENT AUDITOR'S REPORT

To,

THE MEMBERS OF STELLON BIOTECH INC.,

FOREIGN SUBSIDIARY OF CONCORD BIOTECH LIMITED

Independent Auditor's Report on Special Purpose Financial Statements

Opinion


We have audited the financial statements of **Stellon Biotech Inc.** (the Company), which comprise the balance sheet as at March 31, 2026, and the statement of profit and loss for the year then ended, and a summary of the significant accounting policies and other explanatory information (herein after referred to as "Financial Statements"). The company is incorporated in United States of America which is subsidiary of Concord Bio-tech Limited, India.

The books of the company are maintained and prepared in the USA where, as per The Federal and State Law under AICPA mandates the statutory audit of the company under following:

- Public Companies: Companies listed on stock exchanges (e.g., NYSE, NASDAQ) are legally required to submit audited financial statements;
- Private Companies: A bank typically requires an audit if a company's loan size exceeds \$5 million to \$10 million. Private equity or venture capital firms may also require an annual audit;
- Nonprofits & Non-Federal Entities (Single Audit / Federal Awards): A Single Audit is a comprehensive financial and compliance audit required for non-federal entities — such as state and local governments, nonprofits, universities, and tribal organizations — that expend a certain amount of federal funds in a fiscal year;
- State-Level Requirements (Nonprofits): In the United States, some states require nonprofits to submit copies of audited financial statements in order to engage in fundraising activities; and
- For-Profit Entities Receiving Federal Awards: For-profit entities that receive federal awards continue to follow the funding agency's contract and agreement provisions and may be subject to agency-specific audit requirements that have different audit thresholds

The company has not volunteered for appointment of statutory auditor as they do not fall under mandated terms and conditions as per the above Law.

As per Notification No. FEMA 400/2022-RB of Foreign Exchange Management (Overseas Investment) Regulations, 2022 we are appointed as special purpose auditor.



In our opinion and to the best of our information and according to the explanations given to us, the accompanying financial statements give a true and fair view of the state of affairs of the Company as at March 31, 2026, and its results of operations for the year then ended in accordance with the basis of preparation on Ind AS of the financial statements of the Company as at March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SA) issued by the Institute of Chartered Accountants of India ('ICAI') and in particular SA 800 "Special Considerations – Audit of Financial Statements prepared in accordance with Special Purpose Frameworks. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India and have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter - Basis of Accounting and Restriction on Distribution and Use


We draw attention to the financial statements, which describes the basis of accounting. The books of the company are maintained and prepared in the United States, as per Generally Accepted Accounting Principles (GAAP). The financial statements are prepared as per Ind AS to assist the Company to meet the requirements of Regulator under Notification No. FEMA 400/2022-RB of Foreign Exchange Management (Overseas Investment) Regulations, 2022. As a result, the financial statements may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Other Matter

These financial statements do not constitute a set of statutory financial statements in accordance with the local laws in which the Company is incorporated and are prepared for the sole purpose to assist the Company to meet the requirements of Regulator under Notification No. FEMA 400/2022-RB of Foreign Exchange Management (Overseas Investment) Regulations, 2022.

Management's Responsibility for the Financial Statements

The Board of Directors of the Company is responsible for the preparation and presentation of the financial statements that give a true and fair view of the state of affairs and statement of profit and loss of the Company in accordance with the financial reporting provisions of as per Generally Accepted Accounting Principles (GAAP); the Board has prepared the financial statement as per Ind AS this includes the design, implementation and maintenance of internal control relevant to the



preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is also responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for (i) overseeing the Company's financial reporting process, (ii) the maintenance of such records as prescribed under the Guidelines issued by RBI, and (iii) the compliance of the Guidelines.


Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our



conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

FOR M A A K & ASSOCIATES
(Chartered Accountants)
Reg No. :135024W



Date: 27/05/2026
Place: Ahmedabad

A handwritten signature in black ink, appearing to read "Archit Shah", written over a horizontal line.

CA ARCHIT SHAH
Partner
M.No.: 137390
UDIN: 26137390EWTPRH6578



Stellon Biotech Inc.

STELLON BIOTECH INC	
CIN No. Registered Office	
STATEMENT OF ASSETS AND LIABILITIES	
(Rs. in lakhs)	
Particulars	As at 31st March 2026
ASSETS	
1) Non-current assets	
(a) Property, Plant and Equipment	8.39
(b) Right of Use Assets	95.08
(c) Capital work-in-progress	-
(d) Intangible assets under development	-
(e) Financial Assets	
(i) Investments	-
(ii) Loans	-
(iii) Security Deposit	6.98
(iv) Other Financial Assets	-
(f) Deferred Tax Assets	293.66
(g) Other non-Current Assets	-
2) Current assets	
(a) Inventories	-
(b) Financial Assets	
(i) Trade receivables	-
(ii) Cash and cash equivalents	-
(iii) Bank balances other than (ii) above	425.13
(iv) Loans	-
(v) Other Financial Assets	-
(c) Other current assets	36.35
Total Assets	865.57
EQUITY AND LIABILITIES	
Equity	
(a) Equity Share capital	1.71
(b) Other Equity	(775.21)
LIABILITIES	
1) Non-current liabilities	
(a) Financial Liabilities	
(i) Borrowings	1,419.81
(ia) Lease Liability	39.54
(ii) Other financial liabilities (other than those specified in item (b), to be specified)	-
(b) Provisions	-
(c) Deferred tax liabilities (Net)	-
2) Current liabilities	
(a) Financial Liabilities	
(i) Borrowings	56.21
(ia) Lease Liability	49.32
(ii) Trade payables	37.86
(iii) Other financial liabilities	36.33
(b) Other current liabilities	-
(c) Provisions	-
(d) Current Tax Liabilities (Net)	-
Total Equity and Liabilities	865.57
Date : 27/05/2026 Place : Ahmedabad For MAAK & Associates Chartered Accountants Firm's Registration No. 135024W CA Archit Shah Partner Membership No. 137390 UDIN-26137390EWTPRH6578 By the order of the Board Stellon Biotech INC Sanjeev Krishan (CEO) 27 MAY 2026	




Stellon Biotech Inc.

STELLON BIOTECH INC			
CIN No. Registered Office			
FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER ENDED ON March 31, 2026			
PART - I		(Rs. in lakhs)	(Rs. in lakhs)
Sr. No.	Particulars	Quarter ended	Year ended
		31.03.2026	31.03.2026
		(Unaudited)	(Audited)
I.	INCOME		
	(a) Revenue from operations	-	-
	(b) Other Income	0.74	1.43
	Total Income	0.74	1.43
II.	EXPENSES		
	(a) Purchases of Stock-in-trade	-	-
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	-	-
	(c) Employee benefit expense	278.81	718.05
	(d) Finance costs	18.27	36.45
	(e) Depreciation and amortisation expense	0.58	1.18
	(f) Impairment expenses/losses	-	-
	(g) Other expenses	114.43	242.51
	Total Expenses (a to g)	412.08	998.19
III.	Profit before exceptional items and tax (I) - (II)	(411.34)	(996.76)
IV.	Exceptional Items	-	-
V.	Profit before tax (III) - (IV)	(411.34)	(996.76)
VI.	Tax Expense		
	(a) Current tax	-	-
	- Current year	-	-
	- Prior years	-	-
	- MAT Credit (Entitlement)	-	-
	(b) Deferred tax	(283.55)	(273.96)
	Total tax expense	(283.55)	(273.96)
VII.	Profit after tax for the period (V) - (VI)	(127.79)	(722.80)
VIII.	Other comprehensive income		
	A (i) Items that will not be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-
	B (i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(36.63)	(51.83)
	Other comprehensive income, net of tax	(36.63)	(51.83)
IX.	Total comprehensive income for the period	(164.42)	(774.63)
X.	Paid up equity share capital (Face value of Rs. 1 each)	-	-
XI.	Reserves i.e. Other Equity	-	-
XII.	Earnings per equity share (Face value of Rs. 1 each)		
	(1) Basic	-	-
	(2) Diluted	-	-

Date : 27/05/2026
Place : Ahmedabad
For M A A K & Associates
Chartered Accountants
Firm's Registration No. 135024W

CA Archit Shah
Partner
Membership No. 137390

UDIN-26137390EWTPRH6578



By order of the Board
Stellon Biotech INC

Sanjeev Krishan

Sanjeev Krishan
(CEO)

27 May 2026



Stellon Biotech Inc.

STELLON BIOTECH INC

CIN No

Registered Office


CASH FLOW STATEMENT

Particulars	For the Quarter ending 31st March, 2026		For the Year ending 31st March, 2026	
	Amount in \$	Amount in Rs. (Lakhs)	Amount in \$	Amount in Rs. (Lakhs)
Cash flow from Operating activities				
NP	-450073.73	-411.37	-1128744.02	-996.79
Add: Non-Cash Expense				
Foreign Exchange Gain/loss				
Depreciation	632.56	0.58	1334.82	1.18
Interest Paid	19993.15	18.27	41271.91	36.45
Working Capital Adj				
Changes in Current Asset	-12633.22	-11.55	-128425.71	-113.41
Changes in Current Liability	49253.66	45.02	211845.83	187.08
Cash generated from operations	-392827.58	-359.04	-1002717.17	-885.50
Cash flow from investing activities				
Purchase of Property, Plant & Equipment	0	0.00	-10195.29	-9.00
Cash generated from Investment	0	0.00	-10195.29	-9.00
Cash flow from financing activities				
Proceeds from other long term liabilities	500000	457.00	1500000	1,324.65
Interest Paid	-19993.15	-18.27	-41271.91	-36.45
Equity	0	0.00	2000	1.77
Cash generated from Financing Activity	480006.85	438.73	1460728.09	1,289.97
Net Cash Flow	87179.27	79.68	447815.63	395.47
Opening Cash Balance	361956.35	325.47	1319.99	1.13
Effects of Exchange rate changes on cash and cash equivalent		19.97		28.53
Closing Cash Balance	449135.62	425.13	449135.62	425.13

Date : 27/05/2026
Place : Ahmedabad

For MAAK & Associates
Chartered Accountants
Firm's Registration No. 135024W

CA Archit Shah
Partner
Membership No. 137390
UDIN-26137390EWTPRH6578



By order of the Board
Stellon Biotech INC

Sanjeev Krishan
Sanjeev Krishan
(CEO) 27 May 2026